CORVUS PHARMACEUTICALS INC
NASDAQ: CRVS (Corvus Pharmaceuticals, Inc.)
Last update: 15 minutes ago8.37
-0.03 (-0.36%)
| Previous Close | 8.40 |
| Open | 8.37 |
| Volume | 1,819,693 |
| Avg. Volume (3M) | 1,030,025 |
| Market Cap | 625,087,232 |
| Price / Book | 8.85 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Diluted EPS (TTM) | -1.03 |
| Total Debt/Equity (MRQ) | 2.34% |
| Current Ratio (MRQ) | 4.90 |
| Operating Cash Flow (TTM) | -28.53 M |
| Levered Free Cash Flow (TTM) | -13.17 M |
| Return on Assets (TTM) | -39.21% |
| Return on Equity (TTM) | -100.13% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Corvus Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 0.5 |
| Average | 1.25 |
|
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 3.83% |
| % Held by Institutions | 48.27% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Orbimed Advisors Llc | 30 Sep 2025 | 7,165,006 |
| Point72 Asset Management, L.P. | 30 Sep 2025 | 6,454,274 |
| Adams Street Partners Llc | 30 Sep 2025 | 3,275,616 |
| Rtw Investments, Lp | 30 Sep 2025 | 2,679,479 |
| Vivo Capital, Llc | 30 Sep 2025 | 2,234,566 |
| Foresite Capital Management Vi Llc | 30 Sep 2025 | 1,731,233 |
| Perceptive Advisors Llc | 30 Sep 2025 | 1,438,595 |
| Sphera Funds Management Ltd. | 30 Sep 2025 | 407,709 |
| 52 Weeks Range | ||
| Median | 16.00 (91.16%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 13 Oct 2025 | 16.00 (91.16%) | Buy | 7.11 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |